CPRX - Catalyst Corp Market Cap to Sales Volume
Catalyst Pharmaceuticals maintains dominance in the rare neuropathology niche through patents and lobbyist support, despite stringent FDA oversight. Growth is driven by the acquisition of new assets and the monetization of exclusive drugs. The current P/S trend clearly demonstrates the market valuation of capitalization to sales, where the indicator reaches 6.40. Logistics efficiency is ensured by the implementation of automated software and robotic packaging.
Analytical breakdowns for Catalyst Pharmaceuticals Inc (CPRX)
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Capital|Short-Term Debt to Capital Catalyst Corp|CPRX - Company Debts|Debt to Net Assets Ratio Catalyst Pharmaceuticals Inc|CPRX - Company Long-Term Debt|Company Current Liabilities Catalyst Pharmaceuticals|Quick Ratio catalystpharma.com
- earnings and valuation multiples information:
CPRX - Net Profit|Future Profit Catalyst Pharmaceuticals|CPRX - P/E Multiple|Projected Price to Earnings Ratio Catalyst Pharma|CPRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Catalyst Pharmaceuticals Inc|CPRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Catalyst Pharmaceuticals|CPRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months catalystpharma.com|CPRX - Earnings growth in current year|Expected earnings per share growth for next year Catalyst Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:catalystpharma.com, CPRX
The P/S ratio compares the market value of Catalyst Pharmaceuticals (CPRX) to its sales volume, demonstrating how much investors are currently pricing in for each unit of revenue. By analyzing the price-to-sales trend, one can assess the premium for the company's drug monopoly status, which in the long term confirms the high market value of the biopharmaceutical business's stable cash flows.
Competitors of Catalyst Pharmaceuticals
Price-to-Revenue Coefficient biogen.com|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Cap to Sales Volume RGC (Regencell Bioscience Ltd)|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Price-to-Sales Ratio VKTX (vikingtherapeutics.com)|SUPN (Supernus) - P/S Multiple|DNLI: Market Capitalization-to-Revenue Ratio|P/S Multiple HRMY|P/S Multiple Biohaven Corp (BHVN)|Price-to-Revenue Ratio Amylyx Pharmaceuticals AMLX|Market Capitalization-to-Revenue Ratio TRVI|PRAX - Price-to-Revenue Ratio|Anavex (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Corp (PRTA) - P/S Multiple|ALEC (Alector Inc.) - P/S Multiple|Market Cap to Revenue annexonbio.com (ANNX)|P/S Multiple OMER|NGNE - Price to Sales|AC Immune Corp - Market Cap to Revenue|P/S Multiple Voyager Corp VYGR|NMRA: Market Cap to Revenue|scilexholding.com - Market Cap to Sales Volume|TVGN: P/S Multiple|ACOG - Price-to-Revenue Coefficient|CGTX (Cognition Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Inhibikase Pharma (IKT)|P/S Multiple SAVA|P/S Multiple assertiotx.com (ASRT)|Price-to-Revenue Ratio Coya Therapeutics COYA|VistaGen Therapeutics, Inc. - Price-to-Revenue Ratio|OVID - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Acumen Pharmaceuticals, Inc ABOS|CRVO: P/S Multiple|Market Cap to Revenue Alterity Therapeutics Limited|Price-to-Revenue Ratio Clene Inc|PepGen Corp - Price-to-Sales Ratio|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|Annovis Bio, Inc. - Market Cap to Revenue|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (Klotho Neurosciences Inc) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Price to Sales Reviva Pharmaceuticals, Inc. (RVPH)|Market Cap to Revenue MTVA|P/S Multiple neuraxis.com|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG (passagebio.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Minerva (NERV) - Price to Sales|Athira Pharma, Inc. - P/S Multiple|addextherapeutics.com (ADXN) - Market Cap to Revenue|ALZN: P/S Multiple|Cyclerion Therapeutics, Inc. (CYCN) - P/S Multiple|Market Cap to Revenue PTIX|KTTA (Pasithea) - Market Cap to Sales Volume|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. - Price-to-Revenue Ratio|CHRO: Market Cap to Revenue|Price to Sales Eliem Therapeutics|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|LBPH - Price-to-Revenue Coefficient|Market Cap to Revenue MRNS|NKGN (NKGen Biotech Inc) - Market Cap to Sales Volume|Market Cap to Revenue NRBO (NeuroBo)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN (trevena.com) - Price-to-Sales Ratio|Vigil Neuro - P/S Multiple|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|CERE: P/S Multiple
